Previous Page  20 / 22 Next Page
Show Menu
Previous Page 20 / 22 Next Page
Page Background

Page 51


Volume 2

Journal of Microbiology and Biotechnology Reports

Microbial Biotechnology 2018

September 17-18, 2018

Microbial Biotechnology & Vaccine Design

September 17-18, 2018 Lisbon, Portugal



World Congress on

Eliminating the vaccine cold-chain distribution hurdle

Francis Eko

Morehouse School of Medicine, USA

Statement of the Problem:

The requirement for vaccines to be kept sufficiently cold (unbroken cold chain) during transport makes

vaccine distribution to some populations (where the vaccines are greatly needed) extremely challenging, if not impossible. Thus,

various strategies are being explored to eliminate the need for the expensive cold chain. We have designed a versatile Vibrio Cholerae

Ghost (VCG) vaccine delivery platform that eliminates the need for the expensive cold chain and thus alleviate cold chain-associated

constraints on global vaccine access. Moreover, this platform is self-adjuvanting and capable of simultaneously delivering multiple

vaccine antigens to the immune system. It also offers an attractive approach for developing combination vaccines, especially against

diseases with epidemiological overlap. Here, we present data showing a VCG-based chlamydial vaccine protects against infertility

in mice.


Groups of mice were Immunized Rectally (IR) with VCG expressing the

Chlamydia trachomatis

porin B and polymorphic

membrane protein D proteins (rVCG-PmpD/PorB) or glycoprotein D from HSV-2 (rVCG-gD2 or gD2) as antigen control. Vaccine

efficacy was assessed by evaluating the intensity and duration of genital chlamydial shedding following intravaginal challenge with

live chlamydiae. Protection against upper genital tract pathology was determined by assessing infertility and tubal inflammation.

Analysis of Variance (ANOVA) was used to compare differences between groups.


We demonstrated that elicited immune effectors following immunization cross-reacted with the serovar E chlamydial

antigen and reduced the length and intensity of genital chlamydial shedding. Moreover, immunization with the VCG-vaccine reduced

the incidence of tubal inflammation and protected mice against Chlamydia-induced infertility.


These results highlight the potential of the VCG platform for eliciting immunity in the female genital tract and

preventing the sequelae of chlamydial infection such as infertility and upper genital tract inflammation.

Pietro Mastroeni, J Microbio and Biotech Rept 2018, Volume 2